Thermo Fisher Scientific Inc. has completed its all-cash acquisition of The Binding Site Group for £2.25 billion ($2.6 billion), enhancing its Specialty Diagnostics segment and projected to increase adjusted earnings per share by 7 cents in the first year. This acquisition follows Thermo Fisher's earlier strategic investments, including PeproTech for $1.85 billion and PPD for $17.4 billion. With a market cap of $164.25 billion and annual revenues of around $40 billion, Thermo Fisher is reinforcing its leadership in the global biotechnology sector.
“Thermo Fisher Scientific · market cap · Thermo Fisher Scientific · $164.25 B”
“Thermo Fisher · was awarded · Distinguished Leadership Award · October 2022”
“Thermo Fisher · has more than · 125,000 colleagues · around the world”
“Thermo Fisher · enables · customers · to make the world healthier, cleaner and safer”
“Thermo Fisher · mobilized · to support pandemic response · with speed at scale”
“Thermo Fisher · produced · vaccines and treatments · during the pandemic”
“Thermo Fisher Scientific Inc · would buy · Binding Site Group · 2.25 billion pounds ($2.6 billion)”
“Thermo Fisher · projected to boost adjusted earnings per share by · 7 cents · on the first full-year of ownership”
“Thermo Fisher · had earlier this year bought · recombinant proteins maker PeproTech · about $1.85 billion”
“Thermo Fisher · spent · about $17.4 billion · to buy clinical research services provider PPD”
“Thermo Fisher Scientific · announced · acquisition of The Binding Site Group · an all-cash transaction valued at £2.25 billion, or $2.6 billion”
“The Binding Site · will become part of · Thermo Fisher's Specialty Diagnostics segment · true”
